Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer

被引:5
作者
Kishigami, Yasuyuki [4 ]
Kondo, Eiji [2 ]
Yamawaki, Takaharu [5 ]
Nagao, Kenji [6 ]
Hirata, Toru [7 ]
Kotaka, Saki [1 ,2 ]
Kondo, Eiji [2 ]
Kawai, Yosuke [3 ]
Okamoto, Kota [2 ]
Suzuki, Shiro [1 ,8 ]
机构
[1] Aichi Canc Ctr Hosp, Dept Gynecol Oncol, Nagoya, Japan
[2] Mie Univ, Sch Med, Dept Obstet & Gynecol, Tsu, Japan
[3] Toyohashi Municipal Hosp, Dept Obstet & Gynecol, Toyohashi, Japan
[4] Toyota Mem Hosp, Dept Obstet & Gynecol, Toyota, Japan
[5] Ise Red Cross Hosp, Dept Obstet & Gynecol, Ise, Japan
[6] Yokkaichi Municipal Hosp, Dept Obstet & Gynecol, Yokaichi, Japan
[7] Kuwana City Med Ctr, Dept Obstet & Gynecol, Kuwana, Japan
[8] Aichi Canc Ctr Hosp, Dept Gynecol Oncol, 1 1 Kanokoden, Chikusa Ward, Nagoya 4648681, Japan
关键词
Uterine Cervical Cancer; Chemotherapy; Bevacizumab; Maintenance; Prognosis; EVALUATING BEVACIZUMAB; RECURRENT; ARM; CARBOPLATIN; CRITERIA;
D O I
10.3802/jgo.2023.34.e60
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Bevacizumab maintenance therapy following platinum-based combination chemotherapy for metastatic, recurrent, or persistent cervical cancer is not recommended as standard therapy. This pilot study aimed to evaluate the efficacy and safety of bevacizumab maintenance therapy and the contribution of the platinum-free interval to the efficacy of subsequent chemotherapy for advanced cervical cancer. Methods: We retrospectively identified 115 patients with metastatic, recurrent, or persistent cervical cancer treated with platinum-paclitaxel chemotherapy plus bevacizumab at 7 institutions between 2015 and 2020. The primary endpoints were overall survival (OS) and progression-free survival (PFS) in patients who received bevacizumab maintenance therapy and those who did not. We also analyzed the adverse events associated with bevacizumab and survival time from the start of subsequent chemotherapy in both groups. Results: Following platinum-paclitaxel plus bevacizumab chemotherapy, 34 patients received bevacizumab maintenance therapy and 81 patients did not. Of the 115 patients, 56 received chemotherapy for subsequent relapse. Although bevacizumab maintenance therapy prolonged PFS (median of 16.0 months vs. 9.0 months, p=0.041), significant differences were not observed in OS (p=0.374). Furthermore, bevacizumab maintenance therapy did not prolong OS and PFS after the start of subsequent chemotherapy (p=0.663 and p=0.136, respectively). Bevacizumab maintenance therapy significantly increased hypertension (p=0.035) and proteinuria (p=0.005) but did not cause complications leading to death. Conclusion: Bevacizumab single-maintenance therapy for advanced cervical cancer can be considered in selected cases, such as those with acceptable bevacizumab-related side effects. The outcomes of our study will likely contribute to decision-making regarding practical treatment strategies.
引用
收藏
页数:15
相关论文
共 20 条
[1]   Cancer of the cervix uteri [J].
Bhatla, Neerja ;
Aoki, Daisuke ;
Sharma, Daya Nand ;
Sankaranarayanan, Rengaswamy .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2018, 143 :22-36
[2]   Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer [J].
Colombo, N. ;
Dubot, C. ;
Lorusso, D. ;
Caceres, M., V ;
Hasegawa, K. ;
Shapira-Frommer, R. ;
Tewari, K. S. ;
Salman, P. ;
Usta, E. Hoyos ;
Yanez, E. ;
Gumus, M. ;
de Mendoza, M. Olivera Hurtado ;
Samouelian, V ;
Castonguay, V ;
Arkhipov, A. ;
Toker, S. ;
Li, K. ;
Keefe, S. M. ;
Monk, B. J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (20) :1856-1867
[3]   Recurrence Pattern of Cervical Cancer Based on the Platinum Sensitivity Concept: A Multi-Institutional Study from the FRANCOGYN Group [J].
de Foucher, Tiphaine ;
Hennebert, Cecile ;
Dabi, Yohan ;
Ouldamer, Lobna ;
Lavoue, Vincent ;
Dion, Ludivine ;
Canlorbe, Geoffroy ;
Bolze, Pierre Adrien ;
Golfier, Francois ;
Akladios, Cherif ;
Lecointre, Lise ;
Kerbage, Yohan ;
Collinet, Pierre ;
Bricou, Alexandre ;
Carcopino, Xavier ;
Huchon, Cyrille ;
Raimond, Emilie ;
Graesslin, Olivier ;
Owen, Clementine ;
Touboul, Cyril ;
Ballester, Marcos ;
Darai, Emile ;
Bendifallah, Sofiane .
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11)
[4]   Overview of the ethical guidelines for medical and biological research involving human subjects in Japan [J].
Eba, Junko ;
Nakamura, Kenichi .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (06) :539-544
[5]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[6]   Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer [J].
Ilhan, Yusuf ;
Tatli, Ali Murat ;
Teker, Fatih ;
Onder, Arif Hakan ;
Kose, Fatih ;
Geredeli, Caglayan ;
Karaagac, Mustafa ;
Kaplan, Muhammet Ali ;
Inanc, Mevlude ;
Aydin, Sabin Goktas ;
Kargi, Aysegul ;
Arak, Haci ;
Ozturk, Banu ;
Besen, Ali Ayberk ;
Selvi, Oguzhan ;
Korkmaz, Mustafa ;
Oruc, Zeynep ;
Bozkurt, Oktay ;
Bilici, Ahmet ;
Bayram, Selami ;
Dae, Shute Ailia ;
Ozdogan, Mustafa ;
Coskun, Hasan Senol ;
Goksu, Sema Sezgin .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (04) :502-507
[7]   A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis [J].
Ishikawa, Mitsuya ;
Shibata, Taro ;
Iwata, Takashi ;
Nishio, Shin ;
Takada, Toshio ;
Suzuki, Shiro ;
Horie, Koji ;
Kudaka, Wataru ;
Kagabu, Masahiro ;
Tanikawa, Michihiro ;
Kitagawa, Ryo ;
Takekuma, Munetaka ;
Kobayashi, Hiroaki ;
Yaegashi, Nobuo .
GYNECOLOGIC ONCOLOGY, 2021, 162 (02) :292-298
[8]   Investigation of the freely available easy-to-use software 'EZR' for medical statistics [J].
Kanda, Y. .
BONE MARROW TRANSPLANTATION, 2013, 48 (03) :452-458
[9]   Bevacizumab-associated events in Japanese women with cervical cancer: a multi-institutional survey of Obstetrical Gynecological Society of Kinki district, Japan [J].
Mabuchi, Seiji ;
Yamamoto, Misa ;
Murata, Hiroko ;
Yokoe, Takuya ;
Hamanishi, Junzo ;
Terai, Yoshito ;
Imatake, Hikaru ;
Mabuchi, Yasushi ;
Mori, Taisuke ;
Kitada, Fuminori ;
Hashiguchi, Yasuhiro ;
Takahashi, Akimasa ;
Fujiwara, Satoe ;
Naoi, Hirokazu ;
Matsubara, Sho .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (03) :598-605
[10]  
National Cancer Institute, 2022, Common terminology criteria for adverse events (CTCAE) v5.0